Recap: Amarin Q2 Earnings

Shares of Amarin Corp AMRN rose 2.2% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 200.00% over the past year to $0.01, which beat the estimate of ($0.07).

Revenue of $135,317,000 higher by 34.25% from the same period last year, which missed the estimate of $149,480,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Aug 04, 2020

Time: 07:30 AM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2037/35819

Price Action

Company's 52-week high was at $26.12

Company's 52-week low was at $3.95

Price action over last quarter: down 5.72%

Company Overview

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its products include Vascepa.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNews
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!